Rosy Phase 1 results for ImmunoGen drug
17th Nov 2005, 00:10 GMT
ImmunoGen said Wednesday that its investigational drug dubbed huN901-DM1 shows promise in fighting solid tumors.
Rosy Phase 1 results for ImmunoGen drug related news:
- Myriad's Flurizan shows promise in phase 2 — United Press International - Health Business
- Preliminary Results of Ongoing Phase II Study With ZACTIMA in a Rare Form of Thyroid Cancer — StratWire - Business of Healthcare NewsFeed
- Centocor and Schering-Plough drug shows promise in RA — Pharmaceutical Business Review Online
- Pfizer says cholesterol drug promising in trials — Health News Online - Medical and health information and tools from Armenian Medical Network
- GSK says new data back malaria treatment — RedOrbit News - Health
- Anti-MRSA 'Super-drug' Secures Funding to Phase II Clinical Trials — Medical News Today RSS/XML Feed
- Terminally Ill Hope For Miracle — cbs2chicago.com: Chicago news, weather, traffic, video from WBBM-TV: Health
- New Smoking Drug Yields OK Results — Health News: CBSnews.com
- Preliminary Results of Ongoing Phase II Study Show Early Promise With ZD6474 (ZACTIMA[TM]) in a Rare Form of Thyroid Cancer — Presseportal
- Positive phase II results for RenaMed therapy — Pharmaceutical Business Review Online
Latest news from United Press International - Health Business:
- AmerisourceBergen tests Rx tracking plan
- Lilly: Arxxant cuts sight loss in diabetes
- Merck: Arcoxia heart risk same as Voltaren
- Corcept tests psych. major depression Rx
- Neurogen's obesity drug in phase 1 trial
- Analysis: Insurance horizons expanding
- Dendreon seeks OK for Provenge
- Robots caring for stroke patients
- Diabetes drug stalls heart disease
- Diabetes drug also helps arteries